A $2 million CRISPR therapy cannot reach most patients
“这个价格显然无法让大多数本可受益的人用上这种疗法，”她说。
English original
"That is clearly not a price point that will make this available to most people that can benefit from it," she said.
谈及200万美元的镰状细胞CRISPR疗法时
报道摘要
CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body. Jennifer Doudna, who won the 2020 Nobel Prize in chemistry for her work on CRISPR, called ...
CNBC